相关实验视频
Updated: Jul 12, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
在疼痛中探索免疫相互作用的新维度:JAK抑制剂的类潜力
Krasimir Kraev1,2, Mariela Geneva-Popova1,2, Bozhidar Hristov3,4
1Department of Propaedeutics of Internal Diseases "Prof. Dr. Anton Mitov", Faculty of Medicine, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
Life (Basel, Switzerland)
|October 28, 2023
概括
简氏激酶 (JAK) 抑制剂通过向免疫反应来治疗慢性疼痛有望出现. 这篇评论强调了它们调节神经炎症的潜力,并为免疫介导的疼痛条件提供了新的治疗途径.
科学领域:
- 免疫学 免疫学 免疫学
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性疼痛涉及复杂的免疫相互作用和神经炎症.
- 简氏激酶 (JAK) 抑制剂正在成为潜在的治疗药物.
- 了解免疫疼痛途径对于新的治疗策略至关重要.
研究的目的:
- 审查免疫相互作用和慢性疼痛之间的联系.
- 探索Janus激酶 (JAK) 抑制剂在疼痛管理中的潜力.
- 整合从类风湿性关节炎疼痛和中央敏感化的发现.
主要方法:
- 综合免疫学,神经生物学和临床研究的文献综述.
- 对JAK抑制剂对细胞因子抑制和微质调节的影响的分析.
- 对JAK抑制剂在疼痛相关结果中的临床证据的检查.
主要成果:
- 免疫细胞与神经元通信,影响慢性疼痛中的神经炎症反应.
- 雅克抑制剂通过抑制细胞因子和调节微质细胞来证明有效性.
- 临床数据支持JAK抑制剂对疼痛结果的积极影响.
结论:
- 雅克抑制剂为向免疫介导疼痛通路提供了一个有希望的策略.
- 需要进一步的研究来优化JAK抑制剂治疗和阐明免疫-疼痛连接.
- 跨学科的合作对于推动慢性疼痛治疗至关重要.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Combined Effects of Drugs: Antagonism
8.5K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.5K
Analgesia and Pain Management
636
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
636
Drug-Receptor Interactions
5.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.3K
Factors Affecting Protein-Drug Binding: Drug Interactions
173
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
173
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438

